| Year |
Citation |
Score |
| 2021 |
Hinds JW, Ditano JP, Eastman A. Inhibition of Protein Synthesis Induced by CHK1 Inhibitors Discriminates Sensitive from Resistant Cancer Cells. Acs Pharmacology & Translational Science. 4: 1449-1461. PMID 34423276 DOI: 10.1021/acsptsci.1c00150 |
0.469 |
|
| 2021 |
Ditano JP, Sakurikar N, Eastman A. Activation of CDC25A phosphatase is limited by CDK2/cyclin A-mediated feedback inhibition. Cell Cycle (Georgetown, Tex.). 1-12. PMID 34156324 DOI: 10.1080/15384101.2021.1938813 |
0.36 |
|
| 2021 |
Ditano JP, Eastman A. Comparative Activity and Off-Target Effects in Cells of the CHK1 Inhibitors MK-8776, SRA737, and LY2606368. Acs Pharmacology & Translational Science. 4: 730-743. PMID 33860197 DOI: 10.1021/acsptsci.0c00201 |
0.488 |
|
| 2021 |
Ditano JP, Donahue KL, Tafe LJ, McCleery CF, Eastman A. Sensitivity of cells to ATR and CHK1 inhibitors requires hyperactivation of CDK2 rather than endogenous replication stress or ATM dysfunction. Scientific Reports. 11: 7077. PMID 33782497 DOI: 10.1038/s41598-021-86490-x |
0.396 |
|
| 2020 |
Mallick DJ, Eastman A. AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA. Cancers. 12. PMID 32824203 DOI: 10.3390/Cancers12082298 |
0.519 |
|
| 2019 |
Warren NJH, Donahue KL, Eastman A. Differential Sensitivity to CDK2 Inhibition Discriminates the Molecular Mechanisms of CHK1 Inhibitors as Monotherapy or in Combination with the Topoisomerase I Inhibitor SN38. Acs Pharmacology & Translational Science. 2: 168-182. PMID 32259055 DOI: 10.1021/acsptsci.9b00001 |
0.431 |
|
| 2019 |
Warren NJH, Eastman A. Comparison of the different mechanisms of cytotoxicity induced by checkpoint kinase I inhibitors when used as single agents or in combination with DNA damage. Oncogene. PMID 31659257 DOI: 10.1038/S41388-019-1079-9 |
0.529 |
|
| 2019 |
Mallick DJ, Korotkov A, Li H, Wu J, Eastman A. Nuphar alkaloids induce very rapid apoptosis through a novel caspase-dependent but BAX/BAK-independent pathway. Cell Biology and Toxicology. PMID 30826899 DOI: 10.1007/S10565-019-09469-5 |
0.498 |
|
| 2019 |
Mallick DJ, Soderquist RS, Bates D, Eastman A. Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477. Cell Death & Disease. 10: 185. PMID 30796196 DOI: 10.1038/S41419-019-1426-3 |
0.526 |
|
| 2019 |
Warren NJH, Eastman A. Reply to Koh: Signaling dynamics of DNA damage response invoked by combination therapy are dose-dependent. The Journal of Biological Chemistry. 294: 2192. PMID 30737319 DOI: 10.1074/Jbc.Rl119.007419 |
0.303 |
|
| 2018 |
Warren N, Eastman A. Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe. The Journal of Biological Chemistry. PMID 30573684 DOI: 10.1074/Jbc.Ra118.005231 |
0.517 |
|
| 2017 |
Montano R, Khan N, Hou H, Seigne J, Ernstoff MS, Lewis LD, Eastman A. Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor. Oncotarget. 8: 67754-67768. PMID 28978069 DOI: 10.18632/Oncotarget.18834 |
0.457 |
|
| 2017 |
Montano R, Khan N, Hou H, Seigne J, Ernstoff MS, Lewis LD, Eastman A. Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor. Oncotarget. PMID 28711946 DOI: 10.18632/oncotarget.18834 |
0.351 |
|
| 2016 |
Eastman A. Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays. Oncotarget. PMID 27750219 DOI: 10.18632/Oncotarget.12673 |
0.326 |
|
| 2016 |
Bates D, Eastman A. Microtubule destabilizing agents: far more than just anti-mitotic anti-cancer drugs. British Journal of Clinical Pharmacology. PMID 27620987 DOI: 10.1111/Bcp.13126 |
0.319 |
|
| 2016 |
Soderquist RS, Eastman A. BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics. Molecular Cancer Therapeutics. PMID 27535975 DOI: 10.1158/1535-7163.Mct-16-0031 |
0.539 |
|
| 2016 |
Sakurikar N, Eastman A. Critical reanalysis of the methods that discriminate the activity of CDK2 from CDK1. Cell Cycle (Georgetown, Tex.). 15: 1184-8. PMID 26986210 DOI: 10.1080/15384101.2016.1160983 |
0.427 |
|
| 2016 |
Bates D, Feris EJ, Danilov AV, Eastman A. Rapid induction of apoptosis in chronic lymphocytic leukemia cells by the microtubule disrupting agent BNC105. Cancer Biology & Therapy. 17: 291-9. PMID 26891146 DOI: 10.1080/15384047.2016.1139245 |
0.517 |
|
| 2015 |
Sakurikar N, Thompson R, Montano R, Eastman A. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase. Oncotarget. PMID 26595527 DOI: 10.18632/Oncotarget.6364 |
0.517 |
|
| 2015 |
Bates DJ, Lewis LD, Eastman A, Danilov AV. Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemia in vivo. British Journal of Clinical Pharmacology. PMID 25753324 DOI: 10.1111/Bcp.12624 |
0.302 |
|
| 2015 |
Sakurikar N, Eastman A. Will targeting Chk1 have a role in the future of cancer therapy? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1075-7. PMID 25691674 DOI: 10.1200/Jco.2014.60.0767 |
0.548 |
|
| 2015 |
Sakurikar N, Thompson R, Montano R, Eastman A. Abstract 943: The critical role of CDK2 activation in determining the differential sensitivity of cell lines to Chk1 and Wee1 inhibitors Cancer Research. 75: 943-943. DOI: 10.1158/1538-7445.Am2015-943 |
0.42 |
|
| 2014 |
Soderquist RS, Danilov AV, Eastman A. Gossypol increases expression of the pro-apoptotic BH3-only protein NOXA through a novel mechanism involving phospholipase A2, cytoplasmic calcium, and endoplasmic reticulum stress. The Journal of Biological Chemistry. 289: 16190-9. PMID 24778183 DOI: 10.1074/Jbc.M114.562900 |
0.45 |
|
| 2014 |
Godbersen JC, Humphries LA, Danilova OV, Kebbekus PE, Brown JR, Eastman A, Danilov AV. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1576-89. PMID 24634471 DOI: 10.1158/1078-0432.Ccr-13-0987 |
0.41 |
|
| 2014 |
Zaki BI, Suriawinata AA, Eastman AR, Garner KM, Bakhoum SF. Chromosomal instability portends superior response of rectal adenocarcinoma to chemoradiation therapy. Cancer. 120: 1733-42. PMID 24604319 DOI: 10.1002/Cncr.28656 |
0.656 |
|
| 2014 |
Soderquist R, Pletnev AA, Danilov AV, Eastman A. The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA. Apoptosis : An International Journal On Programmed Cell Death. 19: 201-9. PMID 24072590 DOI: 10.1007/S10495-013-0910-Y |
0.512 |
|
| 2014 |
Bates DJP, Feris EJ, Danilov AV, Eastman A. Abstract 834: The microtubule-disrupting drug BNC105 is a potent inducer of acute apoptosis in CLL Cancer Research. 74: 834-834. DOI: 10.1158/1538-7445.Am2014-834 |
0.48 |
|
| 2013 |
Montano R, Thompson R, Chung I, Hou H, Khan N, Eastman A. Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo. Bmc Cancer. 13: 604. PMID 24359526 DOI: 10.1186/1471-2407-13-604 |
0.427 |
|
| 2013 |
Danilov AV, Soderquist RS, Bates DJ, Eastman A. Toward a cure for chronic lymphocytic leukemia: an attack on multiple fronts. Expert Review of Anticancer Therapy. 13: 1009-12. PMID 24053199 DOI: 10.1586/14737140.2013.825424 |
0.354 |
|
| 2013 |
Bates DJ, Danilov AV, Lowrey CH, Eastman A. Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737. Molecular Cancer Therapeutics. 12: 1504-14. PMID 23723123 DOI: 10.1158/1535-7163.Mct-12-1197 |
0.47 |
|
| 2013 |
Soderquist R, Bates DJ, Danilov AV, Eastman A. Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo. Leukemia. 27: 2262-4. PMID 23640104 DOI: 10.1038/Leu.2013.138 |
0.414 |
|
| 2013 |
Thompson R, Eastman A. The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design. British Journal of Clinical Pharmacology. 76: 358-69. PMID 23593991 DOI: 10.1111/Bcp.12139 |
0.474 |
|
| 2013 |
Shabaneh TB, Downey SL, Goddard AL, Screen M, Lucas MM, Eastman A, Kisselev AF. Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib. Plos One. 8: e56132. PMID 23460792 DOI: 10.1371/Journal.Pone.0056132 |
0.471 |
|
| 2013 |
McGowan MM, Eisenberg BL, Lewis LD, Froehlich HM, Wells WA, Eastman A, Kuemmerle NB, Rosenkrantz KM, Barth RJ, Schwartz GN, Li Z, Tosteson TD, Beaulieu BB, Kinlaw WB. A proof of principle clinical trial to determine whether conjugated linoleic acid modulates the lipogenic pathway in human breast cancer tissue. Breast Cancer Research and Treatment. 138: 175-83. PMID 23417336 DOI: 10.1007/S10549-013-2446-9 |
0.345 |
|
| 2013 |
Godbersen C, Eastman A, Brown JR, Danilov AV. Targeting Microenvironment-Mediated NFκb Activation With MLN4924, An Inhibitor Of The Nedd8-Activating Enzyme, In Chronic Lymphocytic Leukemia B Cells Blood. 122: 2875-2875. DOI: 10.1182/BLOOD.V122.21.2875.2875 |
0.439 |
|
| 2013 |
Soderquist RS, Bates DJP, Eastman A. Abstract 4412: S1 and gossypol induce NOXA through increased reactive oxygen species or cytoplasmic calcium and sensitize to ABT-737. Cancer Research. 73: 4412-4412. DOI: 10.1158/1538-7445.Am2013-4412 |
0.504 |
|
| 2013 |
Bates DJ, Danilov AV, Beaulieu BB, Lewis LD, Eastman A. Abstract 3522: Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukemiain vivo. Cancer Research. 73: 3522-3522. DOI: 10.1158/1538-7445.Am2013-3522 |
0.451 |
|
| 2013 |
Eastman A, Montano R, Thompson R, Khan N, Hou H, Lewis LD, Seigne JD, Ernstoff MS. Abstract 3413: Dissecting the combination of gemcitabine and the Chk1 inhibitor MK-8776in vitroandin vivo: cell cycle perturbation and the impact of administration schedule. Cancer Research. 73: 3413-3413. DOI: 10.1158/1538-7445.Am2013-3413 |
0.461 |
|
| 2012 |
Thompson R, Montano R, Eastman A. The Mre11 nuclease is critical for the sensitivity of cells to Chk1 inhibition. Plos One. 7: e44021. PMID 22937147 DOI: 10.1371/Journal.Pone.0044021 |
0.518 |
|
| 2012 |
Chang LJ, Eastman A. Differential regulation of p21 (waf1) protein half-life by DNA damage and Nutlin-3 in p53 wild-type tumors and its therapeutic implications. Cancer Biology & Therapy. 13: 1047-57. PMID 22825333 DOI: 10.4161/Cbt.21047 |
0.802 |
|
| 2012 |
Chang LJ, Eastman A. Decreased translation of p21waf1 mRNA causes attenuated p53 signaling in some p53 wild-type tumors. Cell Cycle (Georgetown, Tex.). 11: 1818-26. PMID 22510560 DOI: 10.4161/Cc.20208 |
0.791 |
|
| 2012 |
Montano R, Chung I, Garner KM, Parry D, Eastman A. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Molecular Cancer Therapeutics. 11: 427-38. PMID 22203733 DOI: 10.1158/1535-7163.Mct-11-0406 |
0.797 |
|
| 2012 |
Reynolds J, Wolf C, Eastman A. Intracellular acidification is associated with, but not required for caspase activation, DNA fragmentation or apoptosis. International Journal of Oncology. 11: 1241-6. PMID 21528329 DOI: 10.3892/Ijo.11.6.1241 |
0.419 |
|
| 2011 |
Bates DJ, Salerni BL, Lowrey CH, Eastman A. Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis. Cancer Biology & Therapy. 12: 314-25. PMID 21768777 DOI: 10.4161/Cbt.12.4.16909 |
0.819 |
|
| 2011 |
Albershardt TC, Salerni BL, Soderquist RS, Bates DJ, Pletnev AA, Kisselev AF, Eastman A. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA. The Journal of Biological Chemistry. 286: 24882-95. PMID 21628457 DOI: 10.1074/Jbc.M111.255828 |
0.808 |
|
| 2011 |
Garner KM, Eastman A. Variations in Mre11/Rad50/Nbs1 status and DNA damage-induced S-phase arrest in the cell lines of the NCI60 panel. Bmc Cancer. 11: 206:1-13. PMID 21619594 DOI: 10.1186/1471-2407-11-206 |
0.759 |
|
| 2011 |
Bates DJP, Lowrey C, Eastman A. Abstract 2138: Vinblastine acutely sensitizes hematopoietic cancers to Bcl-2 targeting drugs Cancer Research. 71: 2138-2138. DOI: 10.1158/1538-7445.Am2011-2138 |
0.523 |
|
| 2010 |
Salerni BL, Bates DJ, Albershardt TC, Lowrey CH, Eastman A. Vinblastine induces acute, cell cycle phase-independent apoptosis in some leukemias and lymphomas and can induce acute apoptosis in others when Mcl-1 is suppressed. Molecular Cancer Therapeutics. 9: 791-802. PMID 20371726 DOI: 10.1158/1535-7163.Mct-10-0028 |
0.811 |
|
| 2010 |
Beyrouthy MJ, Garner K, Hever MP, Freemantle SJ, Eastman A, Dmitrovsky E, Spinella MJ. Abstract 4273: DNA methyltransferase 3B mediates 5-aza-deoxycytidine hypersensitivity in cisplatin-sensitive and cisplatin-resistant pluripotent embryonal carcinoma cells Cancer Research. 70: 4273-4273. DOI: 10.1158/1538-7445.Am10-4273 |
0.762 |
|
| 2010 |
Bates DJP, Lowrey C, Eastman A. Abstract 2993: Vinblastine induces very rapid apoptosis in chronic lymphocytic leukemia and mantle cell lymphoma Cancer Research. 70: 2993-2993. DOI: 10.1158/1538-7445.Am10-2993 |
0.533 |
|
| 2010 |
Eastman A, Montano RE, Garner KM, Chung I, Parry DA. Abstract 2510: Efficacy of the Chk1 inhibitor SCH900776 at abrogating cell cycle arrest and enhancing DNA damage-induced cytotoxicity: Comparison with UCN-01 Cancer Research. 70: 2510-2510. DOI: 10.1158/1538-7445.Am10-2510 |
0.796 |
|
| 2010 |
Albershardt TC, Pletnev AA, Eastman A. Abstract 1040: Most putative BH3 mimetics preferentially antagonize the anti-apoptotic protein MCL-1 rather than BCL-2 Cancer Research. 70: 1040-1040. DOI: 10.1158/1538-7445.Am10-1040 |
0.522 |
|
| 2009 |
Beyrouthy MJ, Garner KM, Hever MP, Freemantle SJ, Eastman A, Dmitrovsky E, Spinella MJ. High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors. Cancer Research. 69: 9360-6. PMID 19951990 DOI: 10.1158/0008-5472.Can-09-1490 |
0.761 |
|
| 2009 |
Garner KM, Pletnev AA, Eastman A. Corrected structure of mirin, a small-molecule inhibitor of the Mre11-Rad50-Nbs1 complex. Nature Chemical Biology. 5: 129-30; author reply. PMID 19219009 DOI: 10.1038/Nchembio0309-129 |
0.693 |
|
| 2009 |
Donnelly C, Olsen AM, Lewis LD, Eisenberg BL, Eastman A, Kinlaw WB. Conjugated linoleic acid (CLA) inhibits expression of the spot 14 (THRSP) and fatty acid synthase genes and impairs the growth of human breast cancer and liposarcoma cells Nutrition and Cancer. 61: 114-122. PMID 19116881 DOI: 10.1080/01635580802348666 |
0.369 |
|
| 2008 |
Zhang WH, Poh A, Fanous AA, Eastman A. DNA damage-induced S phase arrest in human breast cancer depends on Chk1, but G2 arrest can occur independently of Chk1, Chk2 or MAPKAPK2. Cell Cycle (Georgetown, Tex.). 7: 1668-77. PMID 18469532 DOI: 10.4161/Cc.7.11.5982 |
0.491 |
|
| 2008 |
Levesque AA, Fanous AA, Poh A, Eastman A. Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest. Molecular Cancer Therapeutics. 7: 252-62. PMID 18281511 DOI: 10.1158/1535-7163.Mct-07-2066 |
0.54 |
|
| 2007 |
Levesque AA, Eastman AR. p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor? Carcinogenesis. 28: 13-20. PMID 17088261 DOI: 10.1093/Carcin/Bgl214 |
0.473 |
|
| 2006 |
Perez RP, Lewis LD, Beelen AP, Olszanski AJ, Johnston N, Rhodes CH, Beaulieu B, Ernstoff MS, Eastman A. Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 7079-85. PMID 17145831 DOI: 10.1158/1078-0432.Ccr-06-0197 |
0.405 |
|
| 2006 |
Vrana JA, Cleaveland ES, Eastman A, Craig RW. Inducer-and cell type-specific regulation of antiapoptotic MCL1 in myeloid leukemia and multiple myeloma cells exposed to differentiation-inducing or microtubule-disrupting agents. Apoptosis : An International Journal On Programmed Cell Death. 11: 1275-88. PMID 16761109 DOI: 10.1007/S10495-006-7787-Y |
0.48 |
|
| 2005 |
Levesque AA, Kohn EA, Bresnick E, Eastman A. Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints. Oncogene. 24: 3786-96. PMID 15782134 DOI: 10.1038/Sj.Onc.1208451 |
0.815 |
|
| 2004 |
Chatfield K, Eastman A. Inhibitors of protein phosphatases 1 and 2A differentially prevent intrinsic and extrinsic apoptosis pathways. Biochemical and Biophysical Research Communications. 323: 1313-20. PMID 15451440 DOI: 10.1016/J.Bbrc.2004.09.003 |
0.765 |
|
| 2004 |
Eastman A. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. Journal of Cellular Biochemistry. 91: 223-31. PMID 14743382 DOI: 10.1002/Jcb.10699 |
0.492 |
|
| 2003 |
Howell DP, Krieser RJ, Eastman A, Barry MA. Deoxyribonuclease II is a lysosomal barrier to transfection. Molecular Therapy : the Journal of the American Society of Gene Therapy. 8: 957-63. PMID 14664798 DOI: 10.1016/J.Ymthe.2003.09.011 |
0.472 |
|
| 2003 |
Ganju N, Eastman A. Zinc inhibits Bax and Bak activation and cytochrome c release induced by chemical inducers of apoptosis but not by death-receptor-initiated pathways. Cell Death and Differentiation. 10: 652-61. PMID 12761574 DOI: 10.1038/Sj.Cdd.4401234 |
0.799 |
|
| 2003 |
MacLea KS, Krieser RJ, Eastman A. A family history of deoxyribonuclease II: surprises from Trichinella spiralis and Burkholderia pseudomallei. Gene. 305: 1-12. PMID 12594037 DOI: 10.1016/S0378-1119(02)01233-7 |
0.707 |
|
| 2003 |
MacLea KS, Krieser RJ, Eastman A. Structural requirements of human DNase II alpha for formation of the active enzyme: the role of the signal peptide, N-glycosylation, and disulphide bridging. The Biochemical Journal. 371: 867-76. PMID 12558498 DOI: 10.1042/Bj20021875 |
0.684 |
|
| 2003 |
Kohn EA, Yoo CJ, Eastman A. The protein kinase C inhibitor Gö6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Research. 63: 31-5. PMID 12517773 |
0.831 |
|
| 2002 |
Eastman A, Kohn EA, Brown MK, Rathman J, Livingstone M, Blank DH, Gribble GW. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01. Molecular Cancer Therapeutics. 1: 1067-78. PMID 12481430 |
0.838 |
|
| 2002 |
Krieser RJ, MacLea KS, Longnecker DS, Fields JL, Fiering S, Eastman A. Deoxyribonuclease IIalpha is required during the phagocytic phase of apoptosis and its loss causes perinatal lethality. Cell Death and Differentiation. 9: 956-62. PMID 12181746 DOI: 10.1038/Sj.Cdd.4401056 |
0.749 |
|
| 2002 |
Kohn EA, Ruth ND, Brown MK, Livingstone M, Eastman A. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. The Journal of Biological Chemistry. 277: 26553-64. PMID 11953432 DOI: 10.1074/jbc.M202040200 |
0.825 |
|
| 2002 |
MacLea KS, Krieser RJ, Eastman A. Revised structure of the active form of human deoxyribonuclease IIalpha. Biochemical and Biophysical Research Communications. 292: 415-21. PMID 11906178 DOI: 10.1006/Bbrc.2002.6687 |
0.734 |
|
| 2002 |
Ganju N, Eastman A. Bcl-X(L) and calyculin A prevent translocation of Bax to mitochondria during apoptosis. Biochemical and Biophysical Research Communications. 291: 1258-64. PMID 11883953 DOI: 10.1006/Bbrc.2002.6584 |
0.79 |
|
| 2002 |
Stadheim TA, Suh N, Ganju N, Sporn MB, Eastman A. The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells. The Journal of Biological Chemistry. 277: 16448-55. PMID 11880365 DOI: 10.1074/Jbc.M108974200 |
0.807 |
|
| 2001 |
Krieser RJ, MacLea KS, Park JP, Eastman A. The cloning, genomic structure, localization, and expression of human deoxyribonuclease IIbeta. Gene. 269: 205-16. PMID 11376952 DOI: 10.1016/S0378-1119(01)00434-6 |
0.68 |
|
| 2000 |
Sugiyama K, Shimizu M, Akiyama T, Tamaoki T, Yamaguchi K, Takahashi R, Eastman A, Akinaga S. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation. International Journal of Cancer. 85: 703-9. PMID 10699952 DOI: 10.1002/(Sici)1097-0215(20000301)85:5<703::Aid-Ijc17>3.0.Co;2-7 |
0.509 |
|
| 1999 |
Lee SI, Brown MK, Eastman A. Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines. Biochemical Pharmacology. 58: 1713-21. PMID 10571245 DOI: 10.1016/S0006-2952(99)00258-0 |
0.519 |
|
| 1999 |
Krieser RJ, Eastman A. Cleavage and nuclear translocation of the caspase 3 substrate Rho GDP-dissociation inhibitor, D4-GDI, during apoptosis. Cell Death and Differentiation. 6: 412-9. PMID 10381642 DOI: 10.1038/Sj.Cdd.4400515 |
0.485 |
|
| 1999 |
Wolf CM, Eastman A. The temporal relationship between protein phosphatase, mitochondrial cytochrome c release, and caspase activation in apoptosis. Experimental Cell Research. 247: 505-13. PMID 10066378 DOI: 10.1006/Excr.1998.4380 |
0.455 |
|
| 1999 |
Wolf CM, Eastman A. Intracellular acidification during apoptosis can occur in the absence of a nucleus. Biochemical and Biophysical Research Communications. 254: 821-7. PMID 9920824 DOI: 10.1006/Bbrc.1998.0132 |
0.532 |
|
| 1998 |
Krieser RJ, Eastman A. The cloning and expression of human deoxyribonuclease II. A possible role in apoptosis. The Journal of Biological Chemistry. 273: 30909-14. PMID 9812984 DOI: 10.1074/Jbc.273.47.30909 |
0.48 |
|
| 1998 |
Townsend KJ, Trusty JL, Traupman MA, Eastman A, Craig RW. Expression of the antiapoptotic MCL1 gene product is regulated by a mitogen activated protein kinase-mediated pathway triggered through microtubule disruption and protein kinase C. Oncogene. 17: 1223-34. PMID 9771965 DOI: 10.1038/Sj.Onc.1202035 |
0.414 |
|
| 1997 |
Wolf CM, Morana SJ, Eastman A. Zinc inhibits apoptosis upstream of ICE/CED-3 proteases rather than at the level of an endonuclease. Cell Death and Differentiation. 4: 125-9. PMID 16465218 DOI: 10.1038/Sj.Cdd.4400218 |
0.537 |
|
| 1997 |
McBain JA, Eastman A, Nobel CS, Mueller GC. Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors. Biochemical Pharmacology. 53: 1357-68. PMID 9214697 DOI: 10.1016/S0006-2952(96)00904-5 |
0.478 |
|
| 1997 |
Wolf CM, Reynolds JE, Morana SJ, Eastman A. The temporal relationship between protein phosphatase, ICE/CED-3 proteases, intracellular acidification, and DNA fragmentation in apoptosis. Experimental Cell Research. 230: 22-7. PMID 9013702 DOI: 10.1006/Excr.1996.3401 |
0.501 |
|
| 1996 |
Reynolds JE, Li J, Eastman A. Detection of apoptosis by flow cytometry of cells simultaneously stained for intracellular pH (carboxy SNARF-1) and membrane permeability (Hoechst 33342). Cytometry. 25: 349-57. PMID 8946142 DOI: 10.1002/(Sici)1097-0320(19961201)25:4<349::Aid-Cyto6>3.0.Co;2-8 |
0.394 |
|
| 1996 |
Reynolds JE, Eastman A. Intracellular calcium stores are not required for Bcl-2-mediated protection from apoptosis. The Journal of Biological Chemistry. 271: 27739-43. PMID 8910367 DOI: 10.1074/Jbc.271.44.27739 |
0.385 |
|
| 1996 |
McBain JA, Eastman A, Simmons DL, Pettit GR, Mueller GC. Phorbol ester augments butyrate-induced apoptosis of colon cancer cells International Journal of Cancer. 67: 715-723. PMID 8782664 DOI: 10.1002/(Sici)1097-0215(19960904)67:5<715::Aid-Ijc21>3.0.Co;2-2 |
0.497 |
|
| 1996 |
Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. Journal of the National Cancer Institute. 88: 956-65. PMID 8667426 DOI: 10.1093/Jnci/88.14.956 |
0.483 |
|
| 1996 |
Morana SJ, Wolf CM, Li J, Reynolds JE, Brown MK, Eastman A. The involvement of protein phosphatases in the activation of ICE/CED-3 protease, intracellular acidification, DNA digestion, and apoptosis. The Journal of Biological Chemistry. 271: 18263-71. PMID 8663484 DOI: 10.1074/Jbc.271.30.18263 |
0.498 |
|
| 1996 |
Reynolds JE, Li J, Craig RW, Eastman A. BCL-2 and MCL-1 expression in Chinese hamster ovary cells inhibits intracellular acidification and apoptosis induced by staurosporine. Experimental Cell Research. 225: 430-6. PMID 8660932 DOI: 10.1006/Excr.1996.0194 |
0.535 |
|
| 1995 |
Li J, Eastman A. Apoptosis in an interleukin-2-dependent cytotoxic T lymphocyte cell line is associated with intracellular acidification. Role of the Na(+)/H(+)-antiport. The Journal of Biological Chemistry. 270: 3203-11. PMID 7852405 DOI: 10.1074/Jbc.270.7.3203 |
0.419 |
|
| 1995 |
Eastman A. Assays for DNA fragmentation, endonucleases, and intracellular pH and Ca2+ associated with apoptosis. Methods in Cell Biology. 46: 41-55. PMID 7609659 DOI: 10.1016/S0091-679X(08)61923-8 |
0.327 |
|
| 1995 |
Eastman A. Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis. Seminars in Cancer Biology. 6: 45-52. PMID 7548841 DOI: 10.1006/Scbi.1995.0006 |
0.384 |
|
| 1995 |
Yang L, Douple EB, O'Hara JA, Crabtree RA, Eastman A. Enhanced radiation-induced cell killing by carboplatin in cells of repair-proficient and repair-deficient cell lines. Radiation Research. 144: 230-6. PMID 7480650 DOI: 10.2307/3579263 |
0.308 |
|
| 1995 |
Eastman A. Introduction: Apoptosis in oncogenesis and chemotherapy Seminars in Cancer Biology. 6: 1. DOI: 10.1006/Scbi.1995.0001 |
0.398 |
|
| 1993 |
Barry MA, Eastman A. Identification of deoxyribonuclease II as an endonuclease involved in apoptosis. Archives of Biochemistry and Biophysics. 300: 440-50. PMID 8424678 DOI: 10.1006/Abbi.1993.1060 |
0.623 |
|
| 1993 |
Chan CL, Wu Z, Ciardelli T, Eastman A, Bresnick E. Kinetic and DNA-binding properties of recombinant human O6-methylguanine-DNA methyltransferase. Archives of Biochemistry and Biophysics. 300: 193-200. PMID 8424652 DOI: 10.1006/Abbi.1993.1027 |
0.334 |
|
| 1992 |
Wu Z, Chan CL, Eastman A, Bresnick E. Expression of human O6-methylguanine-DNA methyltransferase in Chinese hamster ovary cells and restoration of cellular resistance to certain N-nitroso compounds. Molecular Carcinogenesis. 4: 482-8. PMID 1793486 DOI: 10.1002/Mc.2940040612 |
0.391 |
|
| 1992 |
Barry MA, Eastman A. Endonuclease activation during apoptosis: the role of cytosolic Ca2+ and pH. Biochemical and Biophysical Research Communications. 186: 782-9. PMID 1323291 DOI: 10.1016/0006-291X(92)90814-2 |
0.516 |
|
| 1992 |
Eastman A, Barry MA. The origins of DNA breaks: a consequence of DNA damage, DNA repair, or apoptosis? Cancer Investigation. 10: 229-40. PMID 1316202 DOI: 10.3109/07357909209032765 |
0.606 |
|
| 1991 |
Jennerwein MM, Eastman A, Khokhar AR. The role of DNA repair in resistance of L1210 cells to isomeric 1,2-diaminocyclohexaneplatinum complexes and ultraviolet irradiation. Mutation Research. 254: 89-96. PMID 1986276 DOI: 10.1016/0921-8777(91)90044-P |
0.404 |
|
| 1991 |
Eastman A. Analysis and quantitation of the DNA damage produced in cells by the cisplatin analog cis-[3H]dichloro(ethylenediamine)platinum (II). Analytical Biochemistry. 197: 311-315. PMID 1785684 DOI: 10.1016/0003-2697(91)90397-C |
0.362 |
|
| 1990 |
Müller R, Gust R, Bernhardt G, Keller C, Schönenberger H, Seeber S, Osieka R, Eastman A, Jennerwein M. [DL-1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. Journal of Cancer Research and Clinical Oncology. 116: 237-44. PMID 2370248 DOI: 10.1007/Bf01612897 |
0.383 |
|
| 1990 |
Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochemical Pharmacology. 40: 2353-62. PMID 2244936 DOI: 10.1016/0006-2952(90)90733-2 |
0.651 |
|
| 1990 |
Dabholkar M, Eastman A, Reed E. Host-cell reactivation of cisplatin-damaged pRSVcat in a human lymphoid cell line. Carcinogenesis. 11: 1761-4. PMID 2170046 DOI: 10.1093/Carcin/11.10.1761 |
0.435 |
|
| 1990 |
Eastman A. Alkylating and platinum-based agents. Current Opinion in Oncology. 2: 1109-1114. PMID 2099841 DOI: 10.1097/00001622-199012000-00014 |
0.339 |
|
| 1990 |
Sorenson CM, Barry MA, Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. Journal of the National Cancer Institute. 82: 749-55. PMID 1691303 DOI: 10.1093/Jnci/82.9.749 |
0.638 |
|
| 1989 |
Sheibani N, Jennerwein MM, Eastman A. DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA. Biochemistry. 28: 3120-4. PMID 2742829 DOI: 10.1021/Bi00433A055 |
0.441 |
|
| 1987 |
Eastman A, Barry MA. Interaction of trans-diamminedichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione. Biochemistry. 26: 3303-7. PMID 3651385 DOI: 10.1021/Bi00386A009 |
0.463 |
|
| 1986 |
Eastman A. Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry. 25: 3912-5. PMID 3741840 DOI: 10.1021/Bi00361A026 |
0.301 |
|
| 1984 |
Mossman BT, Eastman A, Landesman JM, Bresnick E. Effects of crocidolite and chrysotile asbestos on cellular uptake and metabolism of benzo(a)pyrene in hamster tracheal epithelial cells. Environmental Health Perspectives. 51: 331-5. PMID 6315375 DOI: 10.1289/Ehp.8351331 |
0.35 |
|
| 1983 |
Hora JF, Eastman A, Bresnick E. O6-methylguanine methyltransferase in rat liver. Biochemistry. 22: 3759-63. PMID 6615799 DOI: 10.1021/Bi00285A007 |
0.313 |
|
| 1982 |
Ireland CM, Eastman A, Bresnick E. DNA-protein crosslinks induced in a hamster tracheal epithelial cell line by benzo(a)pyrene Biochemical and Biophysical Research Communications. 109: 1291-1296. PMID 6301433 DOI: 10.1016/0006-291X(82)91917-9 |
0.347 |
|
| Show low-probability matches. |